Literature DB >> 10888310

Sensitivity of empirical metrics of rate of absorption in bioequivalence studies.

A Ring1, L Tothfalusi, L Endrenyi, M Weiss.   

Abstract

PURPOSE: The sensitivity and effectiveness of indirect metrics proposed for the assessment of comparative absorption rates in bioequivalence studies [Cmax, Tmax, partial AUC (AUCp), feathered slope (SLf), intercept metric (I)] were originally tested by assuming first-order absorption. The present study re-evaluates their sensitivity performances using the more realistic inverse Gaussian (IG) model characterizing the input process for oral drug administration.
METHODS: Simulations were performed for both the first-order or exponential model (EX) which is determined by only one parameter, the mean absorption time (MAT = 1/k(a)), and the IG model, which additionally contains a shape parameter, the relative dispersion of absorption time distribution (CV2A). Kinetic sensitivities (KS) of the indirect metrics were evaluated from bioequivalence trials (error free data) generated with various ratios of the true parameters (MAT and CV2A) of the two formulations.
RESULTS: The behavior of the metrics was similar with respect to changes in MAT ratios with both models: KS was low with Cmax, moderate with SLf and AUCp, and high with I and Tmax following correction for apparent lag time (Tlag). Changes of the shape parameter CV2A, however, were not detectable by Cmax, Tmax, SLf, and AUCp. Changes in both MAT and CV2A were well reflected by I with CV2A - ratio > 1. I exhibited approximately full KS also with CV2A - ratio < 1 when a correction was first applied for the apparent lag time.
CONCLUSIONS: The time profile of absorption rates is insufficiently characterized by only one parameter (MAT). Indirect metrics which are sensitive enough to detect changes in the scale and shape of the input profile could be useful for bioequivalence testing. Among the tested measures, I is particularly promising when a correction is applied for Tlag.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888310     DOI: 10.1023/a:1007521016985

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

1.  An alternative approach for assessment of rate of absorption in bioequivalence studies.

Authors:  M L Chen
Journal:  Pharm Res       Date:  1992-11       Impact factor: 4.200

2.  Absorption rate vs. exposure: which is more useful for bioequivalence testing?

Authors:  T N Tozer; F Y Bois; W W Hauck; M L Chen; R L Williams
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

3.  The duration of measuring partial AUCs for the assessment of bioequivalence.

Authors:  L Endrenyi; F Csizmadia; L Tothfalusi; A H Balch; M L Chen
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

4.  An improved intercept method for the assessment of absorption rate in bioequivalence studies.

Authors:  P Macheras; M Symillides; C Reppas
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

5.  Update on the statistical analysis of bioequivalence studies.

Authors:  V W Steinijans; D Hauschke
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1990-03

6.  Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers.

Authors:  J Lötsch; M Weiss; G Ahne; G Kobal; G Geisslinger
Journal:  Anesthesiology       Date:  1999-04       Impact factor: 7.892

7.  Evaluation of different metrics as indirect measures of rate of drug absorption from extended release dosage forms at steady-state.

Authors:  C Reppas; L F Lacey; O N Keene; P Macheras; A Bye
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

8.  Bioequivalence: performance of several measures of rate of absorption.

Authors:  F Y Bois; T N Tozer; W W Hauck; M L Chen; R Patnaik; R L Williams
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

9.  The impact of lag time on the estimation of pharmacokinetic parameters. I. One-compartment open model.

Authors:  N G Nerella; L H Block; P K Noonan
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

10.  Metrics comparing simulated early concentration profiles for the determination of bioequivalence.

Authors:  L Endrenyi; F Csizmadia; L Tothfalusi; M L Chen
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

View more
  3 in total

1.  C (max) and t (max) verification using Fibonacci sequence and absorption rate.

Authors:  Tomasz Grabowski; Jerzy J Jaroszewski; Beata Borucka; Hubert Ziółkowski
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-07-14       Impact factor: 2.441

2.  Application of the convection-dispersion equation to modelling oral drug absorption.

Authors:  Jan I Freijer; Teun M Post; Bart A Ploeger; Joost DeJongh; Meindert Danhof
Journal:  Bull Math Biol       Date:  2006-10-06       Impact factor: 1.758

3.  Rationale and conditions for the requirement of chiral bioanalytical methods in bioequivalence studies.

Authors:  Juan José Torrado; María Blanco; Magí Farré; Pere Roset; Alfredo García-Arieta
Journal:  Eur J Clin Pharmacol       Date:  2010-02-27       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.